Qiagen Overview

  • Year Founded
  • 1984

Year Founded

  • Status
  • Public

  • Employees
  • 5,700

Employees

  • Stock Symbol
  • QGEN

Stock Symbol

  • Investments
  • 60

  • Share Price
  • $46.76
  • (As of Friday Closing)

Qiagen General Information

Description

Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).

Contact Information

Website
www.qiagen.com
Formerly Known As
Diagen
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Hulsterweg 82
  • 5912 PL Venlo
  • Netherlands
+31 077
Primary Industry
Biotechnology
Other Industries
Laboratory Services (Healthcare)
Stock Exchange
NYS
Vertical(s)
Life Sciences
Corporate Office
  • Hulsterweg 82
  • 5912 PL Venlo
  • Netherlands
+31 077

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Qiagen Stock Performance

As of 20-Jun-2025, Qiagen’s stock price is $46.76. Its current market cap is $10.1B with 217M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$46.76 $46.55 $37.63 - $49.30 $10.1B 217M 1.44M $0.43

Qiagen Financials Summary

As of 31-Mar-2025, Qiagen has a trailing 12-month revenue of $2B.

In Thousands,
USD 		TTM 31-Mar-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV 8,939,952 10,336,581 10,377,145 11,757,661
Revenue 2,002,874 1,978,214 1,965,311 2,141,518
EBITDA 306,447 300,240 609,563 746,598
Net Income 93,676 83,591 341,303 423,211
Total Assets 5,545,369 5,689,622 6,115,190 6,287,735
Total Debt 1,408,339 1,415,883 1,532,062 1,883,670
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Qiagen Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Qiagen‘s full profile, request access.

Request a free trial

Qiagen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins.
Biotechnology
Venlo, Netherlands
5,700 As of 2025

Austin, TX
 

Louisville, CO
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Qiagen Competitors (14)

One of Qiagen’s 14 competitors is Natera, a Formerly VC-backed company based in Austin, TX.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Natera Formerly VC-backed Austin, TX
Biodesix Formerly VC-backed Louisville, CO
Ambry Genetics Formerly PE-Backed Aliso Viejo, CA
Illumina Formerly VC-backed San Diego, CA
Standard BioTools Formerly VC-backed San Francisco, CA
You’re viewing 5 of 14 competitors. Get the full list »

Qiagen Patents

  • 3,128

    Total Documents Applications and Grants

  • Total Patents Families

  • 1,688

    Granted

  • 233

    Pending

  • Expiring in next 12 mo

Qiagen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4481058-A1 Method, use and device for signal collection in a process utilizing fluorescence at different wavelengths Pending 23-Jun-2023
EP-4477751-A1 Body fluid stabilization and processing Inactive 16-Jun-2023
EP-4435717-A1 Method for providing an analysis of partition image data Pending 24-Mar-2023
EP-4522740-A1 Method of dna fragment size selection Pending 11-May-2022
EP-4457369-A1 Method of detecting urothelial or bladder cancer in a liquid sample Pending 27-Dec-2021 C12Q1/6886
To view Qiagen’s complete patent history, request access »

Qiagen Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Qiagen Investments & Acquisitions (60)

Qiagen’s most recent deal was a Merger/Acquisition with Genoox for . The deal was made on 12-May-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Genoox 12-May-2025 Merger/Acquisition Enterprise Systems (Healthcare)
Verogen 03-Jan-2023 Merger/Acquisition Business/Productivity Software
Blirt 11-May-2022 Merger/Acquisition Biotechnology
Glyphic Biotechnologies 19-Jan-2022 Grant Biotechnology
NeuMoDx Molecular 17-Sep-2020 Merger/Acquisition Diagnostic Equipment
You’re viewing 5 of 60 investments and acquisitions. Get the full list »

Qiagen ESG

Risk Overview

Risk Rating

Updated April, 04, 2025

11.77 | Low Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,673

Rank

Percentile

Pharmaceuticals

Industry

of 844

Rank

Percentile

Laboratory Equipment and Services

Subindustry

of 59

Rank

Percentile

To view Qiagen’s complete esg history, request access »

Qiagen Exits (15)

Qiagen’s most recent exit was on 07-Jan-2019 from Ellume. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Ellume 07-Jan-2019 Completed
ArcherDX 20-Mar-2018 Completed
  • 5 buyers
Exosome Diagnostics 07-Jan-2016 Completed
  • 7 buyers
Biotype Innovation 04-Sep-2015 Completed
  • 2 buyers
AdnaGen 17-Mar-2015 Merger/Acquisition Completed
You’re viewing 5 of 15 exits. Get the full list »

Qiagen Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Verogen San Diego, CA 2017

Qiagen FAQs

  • When was Qiagen founded?

    Qiagen was founded in 1984.

  • Where is Qiagen headquartered?

    Qiagen is headquartered in Venlo, Netherlands.

  • What is the size of Qiagen?

    Qiagen has 5,700 total employees.

  • What industry is Qiagen in?

    Qiagen’s primary industry is Biotechnology.

  • Is Qiagen a private or public company?

    Qiagen is a Public company.

  • What is Qiagen’s stock symbol?

    The ticker symbol for Qiagen is QGEN.

  • What is the current stock price of Qiagen?

    As of 20-Jun-2025 the stock price of Qiagen is $46.76.

  • What is the current market cap of Qiagen?

    The current market capitalization of Qiagen is $10.1B.

  • What is Qiagen’s current revenue?

    The trailing twelve month revenue for Qiagen is $2B.

  • Who are Qiagen’s competitors?

    Natera, Biodesix, Ambry Genetics, Illumina, and Standard BioTools are some of the 14 competitors of Qiagen.

  • What is Qiagen’s annual earnings per share (EPS)?

    Qiagen’s EPS for 12 months was $0.43.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »